The NIH: A Budget Appraisal

Digital Vision President George W. Bush's decision to halt historic increases in the National Institutes of Health budget in fiscal year 2004 raises questions about how much the agency and the researchers it funds should expect to receive in the coming years. With a possible war on the horizon, the economy in a slump, and dreams of future federal surpluses fading, policymakers and scientists suggest that funding other science-related agencies may be a higher priority. Beltway observers also q

Written byEugene Russo
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

President George W. Bush's decision to halt historic increases in the National Institutes of Health budget in fiscal year 2004 raises questions about how much the agency and the researchers it funds should expect to receive in the coming years. With a possible war on the horizon, the economy in a slump, and dreams of future federal surpluses fading, policymakers and scientists suggest that funding other science-related agencies may be a higher priority. Beltway observers also question whether NIH researchers, accustomed to ample funds, should have been better prepared for the inevitable buck in the funding trend.

"This has been forecast from day one, five years ago," says Martin Apple, president of the Council of Scientific Society Presidents. "The question is what have we done to adapt to it. And if the answer is 'nothing,' then it's partially our problem as well as everybody else's."

GOOD FOR THE GANDER President ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies